Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone

Gianluca Tornese, Elena Faleschini, Lorenza Matarazzo, Cristina Bibalo, Giulio Andrea Zanazzo, Marco Rabusin, Giorgio Tonini, Floriana Zennaro, Alessandro Ventura

Research output: Contribution to journalArticlepeer-review

Abstract

Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalNeuropediatrics
Volume46
Issue number2
DOIs
Publication statusPublished - Feb 4 2015

Keywords

  • AT/RT
  • brain tumor
  • NF1
  • recurrence
  • rhGH

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone'. Together they form a unique fingerprint.

Cite this